Inicio › Carcinoma de células escamosas de cabeza y cuello › Kentucky
Ensayos clínicos de Carcinoma de células escamosas de cabeza y cuello en Kentucky
16 estudios sobre Carcinoma de células escamosas de cabeza y cuello buscan participantes en Kentucky.
Ciudades en Kentucky
Texto oficial del estudio (inglés)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- University of Kentucky, Markey Cancer Center (Site # 109), Lexington
- Site#0111, Louisville
- Site#0115, Louisville
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06788990A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- University of Kentucky Medical Center, Lexington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- University of Kentucky Markey Cancer Center, Lexington
ReclutandoFase 3
Edades de 60 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04892173Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutandoFase 2
Edades de 18 a 79 · Todos los sexos · Actualizado el 22 sept 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT05983432Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- CommonSpirit Saint Joseph Hospital - Lexington, Lexington
- y 6 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT02734537A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- St. Elizabeth Healthcare, Edgewood
- Norton Cancer Institute, Louisville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06769698Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- University of Kentucky/Markey Cancer Center, Lexington
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Baptist Health Hardin, Elizabethtown
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT07441681Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Norton Cancer Institute, Louisville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jul 2026 · NCT04198766A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- Norton Cancer Institue Downtown, Louisville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT06747585Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT05005403A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Lexington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 may 2026 · NCT06256588A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- University of Kentucky Markey Cancer Center, Lexington
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT06778863A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 115, Louisville
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 nov 2025 · NCT05914116De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.